Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Use of drug-eluting stents in acute myocardial infarction with persistent ST-segment elevation: results of the ALKK PCI-registry.

Härle T, Zeymer U, Schwarz AK, Lüers C, Hochadel M, Darius H, Kasper W, Hauptmann KE, Andresen D, Elsässer A.

Clin Res Cardiol. 2014 May;103(5):373-80. doi: 10.1007/s00392-014-0664-8. Epub 2014 Jan 17.

PMID:
24435358
2.

Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.

Sabaté M, Räber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M, Iñiguez A, Tüller D, Serra A, Baumbach A, von Birgelen C, Hernandez-Antolin R, Roffi M, Mainar V, Valgimigli M, Serruys PW, Jüni P, Windecker S.

JACC Cardiovasc Interv. 2014 Jan;7(1):55-63. doi: 10.1016/j.jcin.2013.07.012. Epub 2013 Dec 11.

3.

Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction.

Hannan EL, Racz M, Walford G, Holmes DR, Jones RH, Sharma S, Katz S, King SB 3rd.

JACC Cardiovasc Interv. 2008 Apr;1(2):129-35. doi: 10.1016/j.jcin.2008.01.006.

4.

Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group.

Brodie BR, Stuckey T, Downey W, Humphrey A, Nussbaum M, Laurent S, Bradshaw B, Metzger C, Hermiller J, Krainin F, Juk S, Cheek B, Duffy P, Simonton CA; Strategic Transcatheter Evaluation of New Therapies (STENT) Group.

Catheter Cardiovasc Interv. 2008 Dec 1;72(7):893-900. doi: 10.1002/ccd.21767.

PMID:
19016465
5.

Safety and effectiveness of drug eluting stent in patients with ST elevation myocardial infarction undergoing primary angioplasty.

Romano M, Buffoli F, Tomasi L, Corrado L, Ferrari MR, Zanini R.

Catheter Cardiovasc Interv. 2008 May 1;71(6):759-63. doi: 10.1002/ccd.21529.

PMID:
18412066
7.

Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction.

Shishehbor MH, Amini R, Oliveria LP, Singh IM, Kelly P, Bhatt DL, Kapadia SR, Ellis SG, Whitlow PL, Brener SJ.

JACC Cardiovasc Interv. 2008 Jun;1(3):227-32. doi: 10.1016/j.jcin.2008.03.011.

8.

Clinical presentation and outcome of patients hospitalized for symptomatic in-stent restenosis treated by percutaneous coronary intervention: comparison between drug-eluting stents and bare-metal stents.

De Labriolle A, Bonello L, Lemesle G, Steinberg DH, Roy P, Xue Z, Kaneshige K, Suddath WO, Satler LF, Kent KM, Pichard AD, Lindsay J, Waksman R.

Arch Cardiovasc Dis. 2009 Mar;102(3):209-17. doi: 10.1016/j.acvd.2009.01.004. Epub 2009 Mar 17.

9.

A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents.

Rathore S, Kinoshita Y, Terashima M, Katoh O, Matsuo H, Tanaka N, Kimura M, Tsuchikane E, Nasu K, Ehara M, Asakura K, Asakura Y, Suzuki T.

EuroIntervention. 2010 Feb;5(7):841-6.

PMID:
20142201
10.

A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).

Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García Del Blanco B, Seidelberger B, Iñiguez A, Gómez-Recio M, Masotti M, Velázquez MT, Sanchís J, García-Touchard A, Zueco J, Bethencourt A, Melgares R, Cequier A, Dominguez A, Mainar V, López-Mínguez JR, Moreu J, Martí V, Moreno R, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C; RIBS V Study Investigators, under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology.

J Am Coll Cardiol. 2014 Apr 15;63(14):1378-86. doi: 10.1016/j.jacc.2013.12.006. Epub 2014 Jan 8.

11.

Paclitaxel-eluting versus bare-metal stents in acute ST elevation myocardial infarction (STEMI).

Hamirani YS, Jibrin I, Abraham D, Merriman B, Wenz C, Bahr RD.

Crit Pathw Cardiol. 2008 Dec;7(4):232-8. doi: 10.1097/HPC.0b013e3181805e0b.

PMID:
19050419
12.

Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group.

Brodie BR, Stuckey T, Downey W, Humphrey A, Bradshaw B, Metzger C, Hermiller J, Krainin F, Juk S, Cheek B, Duffy P, Smith H, Edmunds J, Varanasi J, Simonton CA; STENT (Strategic Transcatheter Evaluation of New Therapies) Group.

JACC Cardiovasc Interv. 2008 Aug;1(4):405-14. doi: 10.1016/j.jcin.2008.06.005. Erratum in: JACC Cardiovasc Interv. 2008 Oct;1(5):601.

13.

Drug-eluting versus bare-metal stents in large coronary arteries of patients with ST-segment elevation myocardial infarction: findings from the ICAS registry.

Abe D, Sato A, Hoshi T, Maruta S, Misaki M, Kakefuda Y, Watabe H, Hiraya D, Sakai S, Kawabe M, Takeyasu N, Aonuma K.

J Cardiol. 2014 Nov;64(5):377-83. doi: 10.1016/j.jjcc.2014.02.020. Epub 2014 Mar 28.

14.

Selective drug-eluting stent implantation for high-risk patients with acute ST-elevation myocardial infarction: rationale and safety.

Prasad SB, David T, Malaiapan Y, Cameron JD, Meredith IT.

Catheter Cardiovasc Interv. 2011 Feb 1;77(2):193-200. doi: 10.1002/ccd.22689.

PMID:
20549694
17.

Safety and efficacy of drug-eluting stent for ST-segment elevation myocardial infarction in an unselected consecutive cohort.

Vlaar PJ, Rihal CS, Singh M, Lennon R, Ting HH, Bresnahan JF, Holmes DR Jr.

Catheter Cardiovasc Interv. 2008 May 1;71(6):764-9. doi: 10.1002/ccd.21479.

PMID:
18412074
18.

A prospective randomized trial of everolimus-eluting stents versus bare-metal stents in octogenarians: the XIMA Trial (Xience or Vision Stents for the Management of Angina in the Elderly).

de Belder A, de la Torre Hernandez JM, Lopez-Palop R, O'Kane P, Hernandez Hernandez F, Strange J, Gimeno F, Cotton J, Diaz Fernandez JF, Carrillo Saez P, Thomas M, Pinar E, Curzen N, Baz JA, Cooter N, Lozano I, Skipper N, Robinson D, Hildick-Smith D; XIMA Investigators.

J Am Coll Cardiol. 2014 Apr 15;63(14):1371-5. doi: 10.1016/j.jacc.2013.10.053. Epub 2013 Nov 21.

19.

Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.

Brodie BR, Wilson H, Stuckey T, Nussbaum M, Laurent S, Bradshaw B, Humphrey A, Metzger C, Hermiller J, Krainin F, Juk S, Cheek B, Duffy P, Simonton CA; STENT Group.

JACC Cardiovasc Interv. 2009 Nov;2(11):1105-12. doi: 10.1016/j.jcin.2009.08.020.

20.

Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis.

Singh IM, Filby SJ, El Sakr F, Gorodeski EZ, Lincoff AM, Ellis SG, Shishehbor MH.

Catheter Cardiovasc Interv. 2010 Aug 1;76(2):257-62. doi: 10.1002/ccd.22509.

Supplemental Content

Support Center